{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:49:24Z","timestamp":1791139764997,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jaad.2023.06.058","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T19:28:01Z","timestamp":1690226881000},"page":"974-983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-4665","authenticated-orcid":false,"given":"Joy Q.","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Roberts-Toler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Yeroushalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hadeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley K.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem G.","family":"Elhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Gondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth B.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Kaffenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell S.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaad.2023.06.058_bib1","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"2022","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jaad.2023.06.058_bib2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatology"},{"key":"10.1016\/j.jaad.2023.06.058_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdin.2022.06.018","article-title":"Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis","volume":"9","author":"Milan","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaad.2023.06.058_bib4","first-page":"1","article-title":"Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis","volume":"00","author":"Adesanya","year":"2022","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.06.058_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2023.06.058_bib6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population","volume":"74","author":"Doshi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.06.058_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.625755","article-title":"Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis","volume":"7","author":"Mourad","year":"2021","journal-title":"Front Med"},{"issue":"3","key":"10.1016\/j.jaad.2023.06.058_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40261-017-0603-3","article-title":"A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis","volume":"38","author":"Hu","year":"2018","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jaad.2023.06.058_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/24755303221131259","article-title":"Factors associated with multi-biologic use in psoriasis patients at an academic medical center and review of biologic survival","volume":"8","author":"Hadeler","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"10.1016\/j.jaad.2023.06.058_bib10","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/09546634.2015.1086476","article-title":"Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: a Belgian perspective","volume":"27","author":"De La Brassinne","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.jaad.2023.06.058_bib11","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2016.02.1221","article-title":"Systematic review of efficacy of anti\u2013tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti\u2013TNF agent","volume":"75","author":"Yamauchi","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.06.058_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"7624","key":"10.1016\/j.jaad.2023.06.058_bib13","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"vonElm","year":"2007","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jaad.2023.06.058_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jaad.2016.10.033","article-title":"Biologic drug survival in Israeli psoriasis patients","volume":"76","author":"Shalom","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2023.06.058_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology:principles, purposes, and pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.06.058_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjd.12422","article-title":"Survival rate of antitumour necrosis factor-\u03b1 treatments for psoriasis in routine dermatological practice: a multicentre observational study","volume":"169","author":"Esposito","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.06.058_bib17","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","article-title":"Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris","volume":"164","author":"Gniadecki","year":"2011","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2023.06.058_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2133.2011.10557.x","article-title":"Drug survival rates of biologic treatments in patients with psoriasis vulgaris","volume":"166","author":"Brunasso","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.06.058_bib19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.13343","article-title":"Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris","volume":"172","author":"Gniadecki","year":"2015","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2023.06.058_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/1346-8138.12353","article-title":"Drug survival rates in patients with psoriasis after treatment with biologics","volume":"40","author":"Umezawa","year":"2013","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2023.06.058_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjd.13001","article-title":"Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis","volume":"171","author":"Menting","year":"2014","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.06.058_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","article-title":"Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry","volume":"86","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.06.058_bib23","article-title":"Systemic consequences of abnormal cholesterol handling: interdependent pathways of inflammation and dyslipidemia","volume":"13","author":"O'Hagan","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jaad.2023.06.058_bib24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.2105\/AJPH.92.8.1238","article-title":"Medicaid managed care and coverage of prescription medications","volume":"92","author":"Buchanan","year":"2002","journal-title":"Am J Public Health"},{"issue":"4","key":"10.1016\/j.jaad.2023.06.058_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jaad.2021.12.017","article-title":"Poor coverage of psoriasis biologics in a cross-sectional analysis of Medicaid formularies","volume":"87","author":"Falotico","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2023.06.058_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-18790-9","article-title":"Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)","volume":"12","author":"Graier","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jaad.2023.06.058_bib27","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of\u00a0psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2023.06.058_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jaad.2022.05.038","article-title":"Similar response to biologic therapy across racial and ethnic groups among patients with psoriasis enrolled in the CorEvitas Psoriasis Registry","volume":"87","author":"Enos","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2023.06.058_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/picr.PICR_87_17","article-title":"Common pitfalls in statistical analysis: logistic regression","volume":"8","author":"Ranganathan","year":"2017","journal-title":"Perspect Clin Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223023939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223023939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:28:28Z","timestamp":1759274908000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223023939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0190962223023939"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.06.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: A 2015-2022 prospective cohort analysis of the CorEvitas psoriasis registry","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}